[TimAlerts] $INVA - Innoviva and GlaxoSmithKline (GSK) report positive top-line results from the pivotal phase III FULFIL study; shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohaler
Received 0 Karma
[TimAlerts] $INVA - Innoviva and GlaxoSmithKline (GSK) report positive top-line results from the pivotal phase III FULFIL study; shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohaler
[TimAlerts] $INVA earnings winner closed right above multi month support yesterday
{text}